Sierra Caroline M, Tan Robert, Eguchi Jim, Bailey Leonard, Chinnock Richard E
School of Pharmacy, Loma Linda University, Loma Linda, CA, USA.
Medical Center, Loma Linda University, Loma Linda, CA, USA.
Pediatr Transplant. 2017 Feb;21(1). doi: 10.1111/petr.12808. Epub 2016 Sep 23.
Pediatric heart transplant patients at our institution are immunosuppressed with a CNI and another immune-modulating agent without utilizing corticosteroids. Patients whose renal function worsened and who did not respond to CNI minimization had their CNI discontinued. The clinical history of 35 pediatric heart transplant patients with significant renal insufficiency whose CNI was discontinued was retrospectively analyzed. Data including serum creatinine and weight were collected before, at time of, and every 3-6 months after CNI discontinuation. This was used to calculate an eGFR. Cardiac allograft rejection and mortality data were also collected. CNI discontinuation occurred 39 times in 35 patients. The median eGFR significantly increased by 14 mL/min 3 months after CNI discontinuation and the increase continued to be significant (P≤.05) at 5 years. Freedom from rejection analysis showed no difference between graft rejection 2 years before versus after CNI discontinuation (P=.437). No mortality was associated with CNI discontinuation. Immunosuppression free of CNIs and corticosteroids appears to be a safe alternative in pediatric heart transplant patients with significant renal insufficiency. Furthermore, this strategy can significantly reverse renal insufficiency, even late after transplantation.
我们机构的小儿心脏移植患者采用钙调神经磷酸酶抑制剂(CNI)和另一种免疫调节剂进行免疫抑制,不使用皮质类固醇。肾功能恶化且对CNI减量无反应的患者停用了CNI。对35例停用CNI的严重肾功能不全小儿心脏移植患者的临床病史进行了回顾性分析。收集了CNI停用前、停用当时以及停用后每3 - 6个月的血清肌酐和体重等数据,用于计算估算肾小球滤过率(eGFR)。还收集了心脏移植排斥反应和死亡率数据。35例患者共停用CNI 39次。停用CNI 3个月后,eGFR中位数显著增加14 mL/min,且在5年时这种增加仍具有显著性(P≤0.05)。无排斥反应分析显示,CNI停用前2年与停用后移植排斥反应无差异(P = 0.437)。停用CNI未导致死亡。对于严重肾功能不全的小儿心脏移植患者,不使用CNI和皮质类固醇的免疫抑制似乎是一种安全的替代方案。此外,即使在移植后期,这种策略也能显著逆转肾功能不全。